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Abstract. Pancreatic ductal adenocarcinoma (PDAC) is an 
aggressive disease with an average survival of 4-6 months 
following diagnosis. Surgical resection is the only treatment 
with curative intent, but resectable PDAC patients are in the 
minority. Also, unlike other neoplasms, PDAC is resistant to 
conventional and targeted chemotherapy. Innovative treat-
ments, such as immunotherapy, can be very important and the 
study of the immune response is fundamental. We previously 
demonstrated that PDAC patients show tumor-infiltrating T 
cells specific to α-enolase (ENO1), a glycolytic enzyme over-
expressed by pancreatic tumor cells, which plays an important 
role in promoting cell migration and cancer metastasis. In the 
present study, we evaluate the functional anticancer proprieties 
of ENO1-specific T cells isolated from the peripheral blood of 
PDAC patients. Furthermore, comparing the T cell receptor 
repertoire of ENO1-specific peripheral and infiltrating tumor 
T cells from the same patient suggests that ENO1-specific T 
cells, despite having a different functional profile, can recir-
culate from the tumor to the periphery. Finally, of clinical 
relevance, the presence of peripheral ENO1-specific T cells 
has a prognostic value and significantly correlates with a 
longer survival.
Introduction
Patients affected by PDAC have an extremely poor prognosis, 
with a 5-year survival rate of only ~ 4-5% and a mean survival 
of 4-6 months. Surgical resection is the only treatment with 
curative intent, but patients with resectable PDAC are in the 
minority (1). Upon tumor resection, the 5-year survival rate 
increases to approximately 15%, while 25% survival is attained 
from treatment with adjuvant chemotherapy (2). There are 
many reasons for such a poor prognosis, including rapid tumor 
dissemination and late diagnosis (3), due to the lack of early, 
disease-specific symptoms. One of the most important features 
of PDAC is the early occurrence of immune suppression that 
affects the T cell-mediated antitumor response. In general, 
immune suppression is manifested in two different ways: 
firstly, by immune suppressive cells, such as regulatory T cells 
(Tregs) and myeloid-derived suppressor cells (MDSC) and 
secondly, by surface regulatory molecules, such as CTLA-4 
and PD-L1. In human PDAC, B7-H1 expression was upregu-
lated and correlated strongly with poor patient prognosis (4) 
while a decrease in the number of CD4+ T cells expressing 
CTLA-4 is associated with improved and disease-free survival 
of PDAC patients (5).
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However, different studies report an antitumor immune 
response in PDAC patients, for example, accumulation of 
CD8+ T cells correlates with increased survival of patients 
(5-7), supporting the protective role of the immune system 
against developing tumors. In fact, usually, the PD-L1 expres-
sion has a significant inverse correlation with CD4+ TILs and 
CD8+ TILs (8,9).
In cancer immunology, the balance of co-stimulatory or 
inhibitory responses is an important underlying mechanism in 
the function of T cell-mediated anticancer immunity.
In particular, the PD-1/PD-L1 axis is one of the prominent 
immune checkpoints, which are known as the inhibitory 
mechanisms of immune responses. The linkage of PD-L1 of 
the  tumor cells with  PD-1 expressed on the activated tumor-
infiltrating lymphocytes (TILs), induces a co-inhibitory signal 
and decreases the level of cytokines, which subsequently results 
in the anergy and apoptosis of the effector T lymphocytes and 
to a poor patient prognosis (10). Thus, although CD8+ T cells 
were thought to be the effective antitumor T-cell subset, some 
studies did not find any correlation between CD8+ T-cells and 
survival rate in patients with pancreatic cancer (11).
The immune response elicited by the deregulated expres-
sion of various tumor-associated antigens (TAA) has been 
demonstrated in different cancers (12,13), including PDAC, as 
shown by serological profiling that identified 29 preferentially 
immunogenic proteins in the serum of PDAC patients (14,15). 
Numerous data have demonstrated that PDAC patients generate 
T/B cells against TAA (16-22), including α-enolase (ENO1) 
which we have previously described (23,24) and that patients 
with anti-TAA antibodies had a better survival rate than the 
antibody-negative patients (25,26). vaccination against ENO1, 
a glycolytic enzyme that plays a role in cell migration and 
cancer metastasis (27), delays tumor progression and signifi-
cantly extends survival in a mouse model of PDAC (28). As 
ENO1 can be considered as a promising candidate for immu-
notherapy in PDAC, information on the antitumor function 
of ENO1-specific T cells from peripheral blood lymphocytes 
may provide a prognostic tool.
Naive CD4+ T cells differentiate into mature Th1, Th2, 
Th17 or Tregs. Th1 cells play an effective anticancer role, while 
Th2, and especially Tregs, suppress immune responses and 
induce tolerance at tumor sites, particularly in PDAC (29,30). 
There are conflicting reports, however, on the role of Th17 
cells in cancer (31), with some studies reporting that higher 
levels of Th17 cells correlate with advanced cancer (32,33), 
while others suggest that Th17 may have a potent antitumor 
effect (34).
The aim of the present study was to characterize the 
phenotypic and functional properties of ENO1-specific T-cells 
isolated from the blood of PDAC patients, evaluating their 
anticancer functional role and to ascertain whether they are 
able to recirculate from the tumor to the periphery and vice 
versa. Finally, we correlated the presence of peripheral anti-
ENO1 T cells with patient survival.
Materials and methods 
Patients. For the present study, we used PBMCs (peripheral 
blood mononuclear cells) from 15 patients (8 males and 7 
females) with pancreatic ductal adenocarcinoma (according to 
the TNM classification for pancreatic tumors) (35), who were 
already enrolled in a previous study approved by the local 
Ethics Committee (24). The age of PDAC patients ranged from 
36 to 92 years (mean age, 63 years). All patients underwent 
surgical resection of the primary lesion but did not receive 
chemotherapy. Patients with evidence of serious illness, 
immunosuppression, autoimmune or infectious diseases 
were excluded. Characteristics of PDAC patients and ENO1 
expression of  PDAC tissue are summarized in Table I. For 
comparison with healthy controls, 15 blood donors (8 males 
and 7 females, mean age 60) were studied.
Reagents. T cell cultures were carried out in RPMI-1640 culture 
medium (SERO-Med GmbH, vienna, Austria) supplemented 
with 10% FCS HyClone Laboratories (Gibco Laboratories, 
Grand Island, NY, USA) and recombinant human interleukin-2 
(IL-2) (Eurocetus, Milan, Italy). Unlabeled or fluorochrome-
conjugated anti-CD3, CD4, CD8, CD25, and isotype-matched 
control mAbs were purchased from BD Biosciences (San Jose, 
CA, USA). Fluorochrome-conjugated anti-IL-10, anti-TGF-β 
and anti-FoxP3 mAbs were purchased from eBioscience 
(San Diego, CA, USA).
Production of recombinant histidine-tagged a-enolase and 
detection of serum anti-ENO1 immunoglobulin G (IgG). 
Recombinant α-enolase was overexpressed in the E. Coli 
strain BL21 (DE3)/pLysS (kindly provided by A. Giallongo, 
Institute of Biomedicine and Molecular Immunology, National 
Research Council, Palermo, Italy) and was produced as previ-
ously reported (23). Anti-ENO1 IgG levels were measured by 
an in-house ELISA kit (23).
Detection of CA19-9 marker. The fasting venous blood (2 ml) 
at the early morning of the study objects was drawn and the 
serum was centrifuged and stored at -20˚C until assayed. The 
electrochemiluminescence immunoassay method was used for 
detecting the levels of CA19-9. The procedures were conducted 
strictly according to the instructions of kits. The critical value 
of CA19-9 was 37 U/ml.
Immunohistochemical analysis of ENO1. Immunohisto-
chemical analysis on 15 PDAC tissues was performed with 
an anti-α-enolase mAb (1:100; clone 19/12) followed by a 
horseradish peroxidase (HRP)-conjugated goat anti-mouse 
IgG (Santa Cruz Biotechnology, Celbio s.p.a., Milan, Italy) 
and DAB detection kit (ventana Medical Systems, Inc., 
Tucson, AZ, USA). Samples were fixed with formalin and 
paraffin-embedded. Slides were incubated with the primary 
and secondary Ab and developed in a ventana ES automated 
stainer. Stained sections were counterstained with hematoxylin.
All images were taken with a x60 objective. Images were 
acquired on a Leica DM LA upright microscope equipped 
with a DC300F camera and were analyzed with IM50 soft-
ware (Leica Microsystems, Heidelberg, Germany).
Detection of ENO1-specific T cells in the peripheral blood of 
patients with PDAC. To assess the presence of ENO1-specific 
T cells in the peripheral blood of PDAC patients, PBMCs 
obtained by density gradient centrifugation on Ficoll-Hypaque 
were re-suspended in medium supplemented with 3% human 
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serum. PBMCs (3x105) were cultured for 96 h in the presence of 
medium alone or ENO1 (10 µg/ml). At 16 h before harvesting, 
0.5 µCi/well [3H]-thymidine (Amersham Pharmacia Biotech, 
Uppsala, Sweden) was added, and the radionuclide uptake 
was measured by a β-counter. The mitogenic index (MI) was 
calculated as the ratio between mean values of cpm (counts 
per minute) obtained in ENO1-stimulated cultures and those 
obtained in the presence of medium alone. An MI ≥3 was 
considered as a positive result.
Generation of ENO1-specific T cell lines and T cell clones 
(Tcc). ENO1-specific T cell lines were generated as previ-
ously described (25). Briefly, 106 PBMCs in 2 ml RPMI-1640 
medium supplemented with 2 mM L-glutamine, 2x10-5 M 
2-ME, and 5% human serum (complete medium) were 
stimulated with ENO1 (10 mg/ml) in 24-well flat-bottomed 
plates for 5 days. Then, human IL-2 (30 U/ml) was added, and 
cultures were maintained for 7 days. viable T-cell blasts were 
re-suspended in complete medium and cloned under limiting 
dilution, as previously described (36). Briefly, single T cell 
blasts were seeded in microwell plates (0.3 cells/well) in the 
presence of 2x105 irradiated (9000 rad) PBMCs, phytohemag-
glutinin (PHA) (0.5% vol/vol) and IL-2 (50 U/ml). At weekly 
intervals, 2x105 irradiated PBMC and IL-2 were added to each 
microculture to maintain the expansion of growing clones.
Tcc were screened for responsiveness to ENO1 by 
measuring [3H]-thymidine uptake after a 60-h co-culture with 
irradiated autologous mononuclear cells in the presence of 
medium or ENO1 (10 mg/ml). An MI ≥3 was considered as a 
positive result.
To verify the clonality of ENO1-specific Tcc, the reper-
toire of the T cell receptor (TCR) vβ chain of single Tcc was 
analyzed with the TCR vβ Repertoire kit (Beckman Coulter, 
Fullerton, CA, USA); isotype-matched non-specific IgG were 
used as negative controls and the T cell blasts were gated by 
anti-CD3 monoclonal antibody.
Characterization of the cytokine profile of Tcc and analysis of 
surface/intracytoplasmic cell markers. We analyzed surface 
marker (CD3, CD4 and CD8) expression in blasts of single 
Tcc by flow cytometry as previously described (37), along 
with the production of the intracellular marker (FoxP3) and 
cytokines (IL-10 and TGF-β) of ENO1-specific Tcc (unable 
to secrete IFN-γ, IL-4 and IL-17). For intracellular analysis, 
blasts were stimulated with PMA (phorbol myristate acetate) 
(10 ng/ml) plus ionomycin (200 ng/ml), and stained with 
anti-IL-10, anti-TGF-β and anti-FoxP3 mAbs. Tcc that were 
negative for FoxP3, IL-10 and TGF-β were defined as T null, 
and Tcc that were positive for FoxP3, IL-10 and TGF-β were 
defined as Tregs.
Table I. Patient characteristics and ENO1-reactivity of T cell clones (Tcc) generated from blood of patients with pancreatic ductal 
adenocarcinoma.
 Overall
 survival Tumor CA19-9 ENO1 Anti-ENO1 ENO1-PBMC  Peripheral ENO1- 
Code  (mo) grade (U/ml) expression IgG proliferation Peripheral Tcc specific Tcc (%)
01.PCp 11 Well 400±21 + ++ Y 16 4 (25)
02.PCp 13 Moderate 420±28 ++ ++ Y 20 5 (25)
03.PCp 8 Poor 570±35 + + N 0 -
04.PCp 7 Well 850±62 +++ + N 10 2 (20)
05.PCp 9 Well 1100±42 +++ + Y 15 3 (20)
06.PCp 8 Moderate 1250±31 ++ + N 0 -
07.PCp 12 Well 210±15 ++ ++ Y 15 5 (33)
08.PCp 8 Moderate 830±68 +++ + Y 10 2 (20)
09.PCp 14 Poor 150±45 +++ +++ Y 20 8 (40)
10.PCp 9 Poor 1350±89 + - N 0 -
11.PCp 10 Well 135±24 + ++ Y 15 6 (40)
12.PCp 11 Poor 216±21 ++ ++ Y 14 4 (29)
13.PCp 8 Well 897±57 +++ + N 10 2 (20)
14.PCp 12 Moderate 235±18 + ++ Y 12 4 (33)
15.PCp 13 Well 326±35 +++ +++ Y 24 9 (38)
All PDAC 10.2 Well 384.6±39 15/15 14/15 10/15  181 54
patients  (47%)   (93%) (67%)  (30%)
PBMC, peripheral blood mononuclear cells; Y, yes, N, no. To rank the presence of anti-ENO1-IgG we referred to a threshold of the OD value 
+ 3SD from 45 age-matched sera from healthy subjects (0.13). The range between 0.13 and the higher value from PC patient sera (0.622) was 
divided in 3 and assigned (+) for OD values between 0.13 and 0.294, (++) for OD between 0.294 and 0.458, and (+++) for OD between 0.458 
and 0.622.
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To evaluate the amount of secreted cytokines, T cell 
blasts of single Tcc were resuspended at a concentration of 
106 cells/ml of medium and cultured for 36 h in the presence of 
PMA (10 ng/ml) plus ionomycin (200 ng/ml). Cell-free super-
natants were collected and assayed in duplicate for IFN-γ, 
IL-4 and IL-17 content by commercial ELISA kits (BioSource 
International, Camarillo, CA, USA). Supernatants presenting 
cytokine levels that were 5 SD above the mean levels in control 
supernatants derived from irradiated APCs alone were consid-
ered positive. Based on the cytokine profile and the CD4/CD8 
expression evaluation, we divided the clones into the following 
groups: Th1/Tc1 (only IFN-γ), Th2/Tc2 (only IL-4), Th0/Tc0 
(IFN-γ and IL-4) and Th17/Tc17 (IL-17).
B-EBV cell preparation. B cells were prepared using the B cell 
isolation kit II (Miltenyi Biotec GmbH, Bergisch Gladbach, 
Germany). To obtain EBv-transformed lymphoblastoid B cell 
lines (EBv-B cells), autologous B cells from each patient were 
incubated for 48 h with EBv-producing marmoset B95.8 cell 
line supernatants, and subsequently expanded in complete 
medium supplemented with 15% FCS.
Perforin-mediated cytotoxicity and Fas-Fas ligand 
(L)-mediated proapoptotic activity. Perforin-mediated cyto-
lytic activity of Tcc was assessed as previously reported (24). 
T cell blasts of ENO1-specific T clones were incubated at an 
effector-to-target ratio of 10-, 5- and 2.5 to-1 with 51Cr-labeled 
autologous (EBv)-B cells pre-incubated with ENO1 (1 µg/ml). 
After centrifugation, microplates were incubated for 8 h at 37˚C, 
and 0.1 ml supernatant was removed from each microculture 
for measuring 51Cr release. To evaluate whether Tcc-specific 
cytotoxicity against target cells was ENO1/HLA-dependent, 
cytotoxicity tests were also carried out under two other 
different conditions: i) with ENO1-pulsed 51Cr-labeled autolo-
gous EBv-B cells in the presence of anti-HLA-DR blocking 
mAbs (10 mg/ml) to evaluate the ENO1-specific CD4+ Tcc; 
ii) in the presence of anti-HLA-A-B-C to assess the ENO1-
specific CD8+ Tcc. Anti-HLA-DR and anti-HLA-A-B-C 
mAbs were purchased from Immunotech (Beckman Coulter, 
Marseille, France).
The ability of ENO1-specific Tcc to induce Fas-FasL-
mediated apoptosis was assessed using Fas+ Panc1 cells as 
targets. T cell blasts from each clone were co-cultured with 
51Cr-labeled Panc1 cells at an effector-to-target ratio of 10-, 5- 
and 2.5- to-1 for 18 h in the presence of PMA (10 ng/ml) and 
ionomycin (200 ng/ml), as previously reported (24). To block 
the Fas-FasL interaction, the anti-Fas antagonistic monoclonal 
antibody M3 (Amgen, Thousand Oaks, CA, USA) was used, at 
a final concentration of 5 mg/ml, for a 30-min pre-treatment of 
51Cr-labeled Panc1 cells, as reported (24).
Suppressive assays. To assess the ability of antigen-specific 
Treg clones to suppress the antigen-induced autologous cell 
proliferation of ENO1-specific effector Tcc, 2x104 of these 
blasts were cultured with 4x103 irradiated (9000 rad) autolo-
gous ENO1-loaded or TT (Tetanus toxoid)-loaded dendritic 
cells (DCs) in the presence of 2x104 cells of ENO1-specific 
Treg. DCs were obtained using the Blood Dendritic Cell 
Isolation kit II (Miltenyi Biotec). At day 4, after 8 h of pulsing 
with 0.5 mCi 3H-TdR/well (Amersham, Little Chalfont, UK), 
cultures were harvested and the radionuclide uptake was 
measured by β-counter analysis. Tetanus toxoid was used for 
specificity control of T cell clones.
DNA extraction and TCR Genescan analysis of TCRβ and 
TCRγ rearrangement. Genomic DNA was extracted from 
ENO1-specific T cell clones obtained from three tumor samples 
and three peripheral blood samples of the same patient using 
the Maxwell 16 Tissue DNA Purification kit and the Maxwell 
16 Instrument (Promega, Madison, WI, USA).
TCR gene rearrangement analysis was performed using a 
gene clonality assay based on the BIOMED-2/Euroclonality 
multiplex-PCR protocol (38), known as the IdentiClone TCRβ 
TCRγ T-Cell Clonality Assa-ABI Fluorescence Detection 
(Invivoscribe, San Diego, CA, USA). The assay consists of 
five tubes each containing primers that target the TCRβ (tubes 
A-B-C) and the TCRγ (tubes D-E) chain locus. Briefly, 100 ng 
of genomic DNA per tube was subjected to PCR amplification 
according to the manufacturer's instructions. PCR products 
were run on an ABI 3130 Genetic Analyzer and Genescan 
profiles were obtained using GeneMapper (version 3.2) soft-
ware (Applied Biosystems, Foster City, CA, USA).
Statistical analysis. Statistical analysis of the mitogenic index 
was evaluated by the unpaired two-tailed Student's t-test. A 
P-value <0.05 was considered statistically significant. A two-
tailed Pearson r coefficient was used to correlate the titer of 
anti-ENO1 IgG and the percentage of ENO1-specific T clones 
obtained from PDAC patients. The correlation between the 
number of ENO1-specific Tcc and survival of patients and 
hazard ratio (HR) were evaluated by Kaplan-Meier analysis 
(log-rank Mentel-Cox test).
Results
ENO1-specific T cells in the peripheral blood of patients with 
PDAC. In order to assess the presence of ENO1-specific T cells 
in the peripheral blood of PDAC patients, PBMCs from 15 
patients, which were previously characterized for the presence 
of tumor infiltrating T cells, (16) were cultured for 5 days in 
the presence of medium alone or recombinant ENO1. Notably, 
PBMCs from 10 of these PDAC patients (67%) (Table I and 
Fig. 1A) proliferated in the presence of ENO1. Conversely, 
in the healthy controls, only 3 cases out of 15 (20%) showed 
proliferation in response to ENO1. In addition, the prolifera-
tion of PBMC of PDAC patients showed a significantly greater 
mitogenic index (mean MI ± SEM, 14.4±2.5) with respect to 
that of the three healthy controls (mean MI ± SEM, 3.3±0.8; 
P=0.0002).
Characterization of Tcc isolated from the blood of PDAC 
patients and reactivity to ENO1. As five PDAC patients did 
not have detectable ENO1-specific T cells in their peripheral 
blood, but four out of these five patients did, however, present 
ENO1-specific tumor-infiltrating T cells (16) we expanded 
and cloned peripheral blood lymphocytes, by IL-2, from all 
PDAC resectable patients; we obtained 181 Tcc from all PDAC 
patients except patients 3, 6 and 10 (Table I). 
There were 88% (159/181) of CD4+ Tcc and 12% of CD8+ 
Tcc (22/181). Interestingly, out of 22 CD8+ Tcc, 7 were isolated 
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from the blood of patient 5 Pcp, who was reported as having 
the highest number of CD8+ Tcc. 
As ENO1 is a TAA that induces an integrated humoral 
and cellular response in PDAC patients (15). Tcc obtained 
were assayed for proliferation in response to ENO1, and 30% 
of the Tcc was (54/181, Table I) proliferated upon stimulation 
with ENO1. With the exception of three cases (Pcp 3,6,10), 
we obtained ENO1-specific Tcc from all patients; in particular 
patients 9 and 15 were recorded as having the greatest number 
of Tcc (8 and 9, respectively). 
Clonality was confirmed by cytofluorimetric analysis of 
TCR-vβ expression. Each Tcc was only revealed by one of 
the TCR-vβ chain-specific monoclonal antibodies, showing a 
single peak of fluorescence intensity (Fig. 1B).
We have already shown that all patients (except for patient 
PCp10) had detectable serum anti-ENO1 IgG (Table I). 
Interestingly, we observed that patients with higher titers of 
anti-ENO1 antibodies also showed the highest percentage 
of ENO1-specific T clones (r=0.8745 and P-value <0.0001) 
(Fig. 1C); particularly patients 9 and 15.
Of the ENO1-specific Tcc, 51 were CD4+, 21 (41%) 
produced IL-17 (Th17) and among these 12 (24%) secreted 
both IL-17 and IFN-γ (Fig. 1D). A total of 15 ENO1-specific 
CD4+ Tcc secreted IL-4, either alone (6 Th2, 12%) or with 
IFN-γ (9 Th0, 18%). Finally, 14 (27%) ENO1-specific CD4+ 
Tcc produced only IFN-γ, showing a Th1 profile. Notably, 
taken together, of the 14 Th1 clones and the 12 Th17 clones 
producing IFN-γ and the 9 Th0 Tcc, we found that the majority 
of ENO1-specific CD4+ Tcc (%) were able to produce IFN-γ. 
The last ENO1-specific CD4+ Tcc was FoxP3+ and produced 
IL-10 and TGF-β, showing a Treg profile. Of the remaining 
three ENO1-specific CD8+ Tcc, one had a regulatory profile 
(defined as Tcreg) and two had a Th1 profile (defined as Tc1) 
(Fig. 1D). 
Functional properties of ENO1-specific T cell clones. To 
evaluate the anticancer properties of the ENO1-specific Tcc 
isolated from the peripheral blood of PDAC patients, we 
assessed their cytotoxicity using ENO1-pulsed 51Cr-labeled 
autologous EBv-B cells as targets. At an effector-to-target 
ratio of 10:1, all 14 Th1, and 7 out of 9 Th0 clones were shown 
to lyse their targets (Fig. 2A). Among the Th17 population, 
only the 12 Tcc IL-17/IFN-γ double producers were able to kill 
their target cells. 
None of the six Th2 or the ENO1-specific Treg Tcc lysed 
the EBV-B cells, while only the two ENO1-specific Tc1 CD8+ 
clones killed the EBv-B cells.
As expected, in the presence of anti-HLA class II blocking 
mAbs, all the ENO1-specific CD4+ Tcc were unable to kill 
the EBv-B cells, and similar results were obtained for the 
two ENO1-specific Tc1 in the presence of anti-HLA class I 
blocking mAbs (Fig. 2A).
Effector T cells can kill their targets by Fas-FasL-mediated 
apoptosis, and therefore, the ability of ENO1-specific Tcc to 
induce 51Cr release by Fas+ Panc1 cells was evaluated. Upon 
mitogen activation, 57% of CD4+ (29/51) and 66% of CD8+ 
(2/3) ENO1-specific Tcc induced apoptosis in target cells 
(Fig. 2B). Among the CD4+ Tcc, 14 were Th1, 12 were Th17, 
and 3 were Th0, but none were Th2 or Treg (Fig. 2B). The role 
of the Fas-FasL interaction in 51Cr release was confirmed by 
its inhibition (range, 38.3-57.6%) using an anti-Fas antibody 
(data not shown).
Finally, we evaluated the ability of the unique ENO1-
specific Treg Tcc (Tcc 6) to inhibit the proliferation of 
ENO1-effector Tcc (Th1 and Th17) obtained from the same 
patient (Pcp 8). As shown in Fig. 2C, the ENO1-specific Treg 
clone inhibited proliferation of both ENO1-specific effector 
Tcc: the Th1 (Tcc 18) and the Th17 (Tcc 24).
TCR analysis of ENO-1 specific Tcc from peripheral blood 
and tumor areas. As ENO1-specific Tcc was detected in both 
the peripheral blood and tumor areas in 73% of the analyzed 
PDA patients (24), we tested the hypothesis that the same T 
cell clones were circulating from the periphery to the tumor 
area and vice versa. We reasoned that if at least one Tcc from 
the periphery and one Tcc from the tumor area of the same 
PDAC patient showed the same rearrangement of their TCR, 
this would provide a proof of concept that the same T lympho-
cyte was able to recirculate from the tumor to the peripheral 
blood and vice versa. 
Three ENO1-specific Tcc (1Th1, 1 Th17 and 1 Tc1) from 
the blood and from the central tumor area of the same PDAC 
patient (Pcp9) were analyzed for TCRβ and γ chain rearrange-
ments by using a classical gene clonality assay (36). Results 
confirmed the identity of the CD8+ Tcc with a Tc1 profile from 
blood and from tumors (Fig. 3).
Figure 1. Detection of ENO1-specific T cells in the blood of PDAC patients 
and profile characterization of ENO1-specific Tcc. (A) The graph represents 
the mitogenic index of PBMC proliferation of  ten PDAC patients and three 
healthy controls. PBMCs were stimulated with ENO1 and an MI ≥3 was 
considered as a positive result. PDAC patients showed a significantly greater 
mitogenic index (P=0.0002). (B) The histogram represents the TCR-vβ 
repertoire of the 54 CD4/CD8 ENO1-specific Tcc isolated from the blood 
of PDAC patients. (C) Correlation between the anti-ENO1 IgG titer and the 
number of ENO1-specific T clones obtained from the same PDAC patient 
(Spearman regression r=0.8745 and P-value <0.0001). (D) Cytokine profile 
distribution of ENO1-specific T cell clones. 
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Prognostic role of peripheral ENO1-specific T cell clones. 
Because the majority of ENO1-specific Tcc specifically killed 
pancreatic cancer cells and were able to re-circulate from 
the periphery to the tumor and vice versa, we evaluated if 
the number of peripheral ENO1-specific Tcc correlated with 
patient survival from diagnosis. 
For this purpose, we divided the patients into two groups 
based on the percentage of peripheral ENO1-specific Tcc and 
on serum anti-ENO1 specific antibodies: i) <20, and ii) >20 
(Table I). Kaplan-Meier analysis revealed that the patients 
of group ii showed a better survival compared to group i 
(P<0.0001, Hazard Ratio=31) suggesting a positive correlation 
between the percentage of circulating ENO1-specific cells 
and a longer survival (Fig. 4). In addition, the levels of serum 
CA19-9 (Table I) in patients of group I were significantly 
(P<0.0001) higher than those in PDAC patients of ii group (data 
not shown). On the contrary, the PDAC expression of ENO1 
is similar in the different patients of the two groups. PDAC 
tissues diffusely expressed α-enolase in the cells lining the 
neoplastic ducts infiltrating the stroma. In other words, Enolase 
is overexpressed in most of PC tissues, and to discriminate 
between high and lower overexpression is difficult. Thus, it is 
not possible to achieve a correlation between the expression of 
Enolase and the presence of specific ENO1-specific Tcc.
Discussion
ENO1 is a PDAC-associated antigen, capable of eliciting 
an anti-PDAC T cell response in situ, as demonstrated in a 
previous study, where we characterized the effector functions 
Figure 2. Functional activities of blood-derived Tcc reactive to ENO1. 
(A) The results are the mean values of percentage-specific 51Cr release at an 
effector-to-target ratio of 10-to-1 in triplicate micro-cultures. The dotted line 
represents three SD over the mean 51Cr release in cultures with 51Cr-labeled 
autologous unpulsed EBv-B cells. (B) To assess their ability to induce apop-
tosis in target cells, 51Cr release was measured as an index of apoptotic target 
cell death. Data of one representative type clone are reported as mean values 
of triplicate micro-cultures. (C) Morphological changes in Panc1 cells after 
co-culture with ENO1-specific Tcc. Typical apoptotic cells with condensed 
or fragmented nuclei are observed in treated cell lines (bottom panel), while 
control cells (top panel) show regular-shaped nuclei. All of the photographs 
are at x200 magnification. (D) ENO1-specific Treg clones suppresses the 
proliferation of autologous ENO1-specific effector T cell clones (Th1 and 
Th17). Results represent mean values and standard deviations of percentage 
inhibition in triplicate micro-cultures.
Figure 3. Analysis of TCR gene rearrangement. Molecular analysis of TCR 
gene rearrangement (BIOMED-2/Euroclonality protocol) of ENO1-specific 
Tcc isolated from the central tumor area and the peripheral blood of the same 
PDAC patient. Genescan profiles of TCRβ (tube A) and TCRγ (tube D) are 
represented. Numbers in square brackets indicate the length of the clonal 
peaks in base pairs (bp). 
Figure 4. Correlation between patient survival and number of peripheral 
ENO1-specific Tcc. To correlate the survival of PDAC patients with the 
number of ENO1-specific Tcc we divided the patients into two groups: i) 
patients with ENO1-specific Tcc (≤20%) and ii) patients with ENO1-specific 
Tcc (>20%). We correlated the different groups using a Kaplan-Meier curve. 
The patients of group ii showed a better survival compared to groups i 
(p<0.00001, Hazard Ratio=31) suggesting a positive correlation between the 
percentage of circulating ENO1-specific cells and a longer survival. 
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of ENO1-specific T-cells isolated from the tumor tissue of 
PDAC patients (24). We showed that ENO1-specific Th1/Th17 
cells have a specific anticancer effector function, but they 
accumulate in the healthy tissue surrounding the cancer cells, 
where, conversely, there are elevated levels of ENO1-specific 
Tregs (24). Based on these observations, we hypothesize 
that the tumor microenvironment negatively influences the 
cytolytic activity of T lymphocytes by promoting the recruit-
ment of specific Treg cells. To investigate this hypothesis, we 
characterized the ENO1-specific peripheral T cell response in 
the same previously-enrolled PDAC patients (24) to ascertain 
whether or not the T reg pool was still maintained.
Firstly, we showed that PBMCs from ten PDAC patients 
were able to proliferate in vitro in the presence of ENO1, while 
only three healthy controls reacted upon antigen stimulation. 
This indicates that most PDAC patients have ENO1-specific 
T cell precursors in their peripheral blood, which can be trig-
gered by in vitro ENO1 re-stimulation. The presence of the 
anti ENO1-precursor appears to be PDAC-specific as very few 
healthy subjects displayed peripheral blood lymphocyte prolif-
eration in response to ENO1 and also, a significantly lower 
index of proliferation.
To gain information on the functional status of anti-ENO1-
specific peripheral T lymphocytes, we obtained ENO1-induced 
T cell lines and subsequently generated Tcc from all PDAC 
patients, with the exception of three patients (Pcp 3, 6 and 10). 
Notably, none of the PBMCs isolated from these three patients 
proliferated in the presence of ENO1, even though ENO1-
specific Tcc were obtained from the tumor area in two (Pcp 3 
and 10) out of the three patients (24). The lack of ENO1-specific 
T cells in the peripheral blood of these patients, is probably 
due to a difference in the migratory pattern of tumor-specific 
T cells (39), or to differences in the tumor microenviron-
ment, in cytokine/chemokine secretion (40) or altered protein 
expression (such as integrins), which circumscribe the immune 
response in situ (41,42).
In addition, we did not analyze ENO1 expression in the 
tumor tissue of our patients, and we therefore cannot exclude 
the possibility that the absence of a T-cell response in one 
patient may result from reduced levels of ENO1 expression. 
We have shown, in fact, that the anti-ENO1 humoral and 
cellular responses are induced as a consequence of enhanced 
ENO1 expression in PDAC tissues (24).
However, the most important result is that the peripheral 
anticancer response is a ‘mirror’ of the intratumoral PDAC-
specific response, clearly demonstrated as the majority of 
patients displayed both immune responses with only two 
exceptions. Thus, analysis of the Tcc of the peripheral immune 
response in PDAC may be an adequate method to determine if 
a patient will have a cancer-specific immune response in situ.
The peripheral blood of PDAC patients has been shown to 
display serum anti-ENO1 IgG autoantibodies (26) and here, we 
provide the first evidence that, in PDAC patients, the overall 
percentage of peripheral ENO1-specific T cells, reaches one 
third of the total Tcc obtained.
With the exception of one patient (Pcp10), all patients had 
detectable serum anti-ENO1 IgG, and interestingly, those with 
higher titers had the highest percentage of ENO1-specific T 
clones, in particular patients 9 and 15.
Remarkably, out of the 54 ENO1-specific Tcc obtained, 
51 were CD4+ and the vast majority of them (69%) displayed 
a Th1/Th17 profile, thus conferring to them a potential anti-
cancer role (43-46). Of the remaining CD8+ Tcc, one displayed 
a Treg profile and two were Tc1.
Previously, we have confirmed the immune-suppressive 
role of the PDAC microenvironment, demonstrating that intra-
tumoral ENO1-specific CD4+ T cells displayed an increased 
number of T null cells and a Treg phenotype (24). On the 
Figure 5. The path of ENO1-specific T cells in pancreatic cancer. Proinflammatory cytokines and chemokines attract T cells specific to ENO1 (and/or to  other 
TAA) from the peripheral blood to the tumor site (1). Under the influence of the tumor microenvironment (which includes stromal cells, extracellular matrix 
and myeloid suppressor cells), the ENO1-specific T cells undergo different fates: some maintain the effector function (gray) while others shift to regulatory 
functions (white), which  prevent  the killing of cancer cells by effector cells and favor cancer cell escape (2). Some of the ENO1-specific Tcc migrate back 
into the bloodstream, where the number of effector T cells increases due to the absence of the immunosuppressive action of the tumor microenvironment (3).
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contrary, the present data demonstrate that, within the same 
patients, circulating ENO1-specific Tcc showed a different 
cytokine profile compared to Tcc isolated from the tumoral 
tissue, with an increased IFN-γ secretion and a decreased 
regulatory profile. In agreement with these findings, we have 
also demonstrated that the few Tc1 and all the ENO1-specific 
IFN-γ-producing CD4+ Tcc had cytotoxic activity and most of 
them induced apoptosis in target cells, showing an effective 
anticancer role.
Of particular relevance, the analysis of TCR rearrange-
ments of some ENO1-specific peripheral and intratumoral Tcc 
from the same PDAC patient confirmed the ability of tumor-
infiltrating lymphocytes to circulate. Therefore, cytotoxic 
ENO1-specific Tcc that reach the tumor could be subsequently 
modified and switched off by different immunosuppressive 
mechanisms including PD-1/PD-L1 (41,42). However, because 
of the retained cytotoxic ability and potential antitumor 
function of peripheral ENO1-specific Tcc, they could be very 
important for the elimination of cancer-circulating cells and 
prevention of metastasis and disease relapse (47,48) (Fig. 5).
Finally, we emphasize that patients with a high number 
of peripheral blood ENO1-specific Tcc showed a significant 
improved survival compared to PDAC patients without or 
with a low number of ENO1-specific Tcc. However, we are 
aware that only a small cohort was employed in the present 
study, and while the presence of Tcc could be considered a 
potential prognostic marker for PDAC, it should be validated 
in a larger cohort of PDAC patients. These results, therefore, 
indicate the relevance of the ENO1-specific immune response 
in the generation of an effective anticancer response, which 
correlates with improved survival of PDAC patients.
In conclusion, we have demonstrated for the first time that, 
in PDAC patients: i) there was a correspondence between the 
intratumoral and peripheral ENO1-specific immune response; 
ii) the same clonal T cells recirculated from the tumor to 
the periphery; and iii) the circulating ENO1-specific T cells 
showed a more effective anticancer role compared to Tcc 
isolated from the tumoral tissue.
These data support the idea that ENO1 could be a good 
candidate antigen for immunotherapeutic treatments in PDAC 
patients (49), in particular after surgical resection to prevent 
relapse of the disease through the marked anticancer activity 
of circulating ENO1-specific Tcc. Additional studies should be 
carried out to identify the different immunosuppressive mech-
anisms that are able to modify or switch off the anticancer 
specific immune response in order to make this immunothera-
peutic approach feasible.
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